Download the Whitepaper and Learn More About A High-Throughput, Radioactivity-Free Assay For Cell-Mediated Cytotoxicity
On a mission to find out what the future holds for the CAR-TCR space, we sat down with: Hans Bishop, CEO, Juno Therapeutics; André Choulika, CEO, Cellectis; Laurence Cooper, CEO, ZIOPHARM and David Chang, CMO, Kite, Pharma to talk shop.
The industry results provide some great insights into manufacturing challenges, key design factors for the next generation of CAR-TCR therapies and pricing models for these therapies.
Stephanie Farnia, Director, Payer Policy, Be the Match Biotherapiesdiscusses payer coverage, coding and reimbursement challenges
Kevin Friedman, Director, bluebird bio is discussing the key considerations of cost, scalability and bioactivity of CAR-T cell manufacturing
Sadik Kassim, former Associate Director, Cell and Gene Therapies Unit at Novartis now VP at Mustang Bio discussed the Characterization of CAR-T Therapies and advancing towards precision.
Kimberly Freeman, VP Commercial Strategy, Adaptimmune
Donna Rill, Vice President of Manufacturing, Cell Medica
Vita Golubovskaya, Robert Berahovich, Shirley Xu, Hizkia Harto and Lijun Wu